{"id":76799,"date":"2026-08-27T14:39:41","date_gmt":"2026-08-27T06:39:41","guid":{"rendered":"https:\/\/flcube.com\/?p=76799"},"modified":"2026-08-27T14:39:41","modified_gmt":"2026-08-27T06:39:41","slug":"cspcs-pd-1-il-15-bispecific-sys6090-jmt108-granted-fda-fast-track-for-mss-pmmr-metastatic-colorectal-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=76799","title":{"rendered":"CSPC&#8217;s PD-1\/IL-15 Bispecific SYS6090 (JMT108) Granted FDA Fast Track for MSS\/pMMR Metastatic Colorectal Cancer"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>CSPC Pharmaceutical Group<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/1093:HKG\">HKG: 1093<\/a>) announced that <strong>SYS6090 (JMT108)<\/strong>, a <strong>PD\u20111\/IL\u201115 bispecific fusion protein<\/strong>, has been granted <strong>Fast Track designation by the U.S. Food and Drug Administration (FDA)<\/strong> for the treatment of patients with <strong>microsatellite\u2011stable (MSS) or proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC)<\/strong> who have progressed on standard systemic therapies. The designation recognizes a differentiated immunotherapy approach aimed at one of oncology&#8217;s most resistant tumor types \u2014 the immunologically &#8220;cold&#8221; MSS\/pMMR mCRC population with profound unmet need.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Regulator<\/td><td><strong>U.S. Food and Drug Administration (FDA)<\/strong><\/td><\/tr><tr><td>Designation<\/td><td><strong>Fast Track<\/strong><\/td><\/tr><tr><td>Asset<\/td><td><strong>SYS6090 (JMT108)<\/strong>, PD\u20111\/IL\u201115 bispecific fusion protein<\/td><\/tr><tr><td>Sponsor<\/td><td><strong>CSPC Pharmaceutical Group<\/strong> (HKG: 1093)<\/td><\/tr><tr><td>Indication<\/td><td><strong>MSS\/pMMR metastatic colorectal cancer (mCRC)<\/strong> after progression on standard systemic therapies<\/td><\/tr><tr><td>Announcement Date<\/td><td>27 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> SYS6090 (JMT108), a bispecific fusion protein<\/li>\n\n\n\n<li><strong>Dual Mechanism:<\/strong> Simultaneously <strong>blocks PD\u20111<\/strong> and <strong>activates the IL\u201115 signaling pathway<\/strong><\/li>\n\n\n\n<li><strong>Structural Innovation:<\/strong> A specifically designed <strong>asymmetric structure<\/strong> precisely directs IL\u201115 activity in a <strong>PD\u20111\u2011dependent fashion<\/strong><\/li>\n\n\n\n<li><strong>Tumor Microenvironment Strategy:<\/strong> Potential to selectively inflame resistant or immunologically <strong>&#8220;cold&#8221;<\/strong> tumor microenvironments and activate exhausted effector cells<\/li>\n\n\n\n<li><strong>Safety Design:<\/strong> PD\u20111\u2011dependent IL\u201115 targeting aims to minimize immune\u2011related toxicity versus systemic IL\u201115 agonism<\/li>\n\n\n\n<li><strong>Positioning:<\/strong> Engineered to overcome the limited responsiveness of MSS\/pMMR tumors to standard immunotherapy<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-unmet-need-mss-pmmr-mcrc\" class=\"wp-block-heading\">Unmet Need \u2013 MSS\/pMMR mCRC<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>&#8220;Cold&#8221; Tumor Challenge:<\/strong> MSS\/pMMR mCRC is typically considered a &#8220;cold&#8221; tumor with limited responsiveness to standard immunotherapy, representing the vast majority of mCRC cases<\/li>\n\n\n\n<li><strong>Poor Prognosis:<\/strong> The median overall survival for patients who have received third\u2011line and subsequent therapies generally remains <strong>under 12 months<\/strong><\/li>\n\n\n\n<li><strong>Significant Unmet Medical Need:<\/strong> The combination of immunotherapy resistance and limited late\u2011line options makes this population a priority area for novel mechanisms<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Fast Track Advantages:<\/strong> The designation grants more frequent FDA interactions, rolling review eligibility, and potential Accelerated Approval and Priority Review pathways \u2014 compressing the potential U.S. registration timeline for SYS6090.<\/li>\n\n\n\n<li><strong>High\u2011Value Niche:<\/strong> MSS\/pMMR mCRC is one of the most commercially significant remaining frontiers in immuno\u2011oncology, where any therapy demonstrating meaningful survival benefit could capture a large underserved patient population.<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> The PD\u20111\u2011dependent IL\u201115 targeting strategy distinguishes SYS6090 within the emerging IL\u201115\/immune\u2011agonist class, balancing tumor inflammation with toxicity control \u2014 a key determinant of clinical success.<\/li>\n\n\n\n<li><strong>Watch Items:<\/strong> Clinical data readouts in late\u2011line MSS\/pMMR mCRC, potential combination strategies with standard therapies, and partnership\/licensing interest for global development following the Fast Track designation.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2013 This brief is for informational purposes only and does not constitute investment or medical advice. Statements regarding clinical development, regulatory pathways, and future approvals are forward\u2011looking and subject to risks and uncertainties; actual results may differ materially. Refer to official announcements from CSPC Pharmaceutical Group and the FDA for authoritative details.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082600826_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026082600826_c.\"><\/object><a id=\"wp-block-file--media-8767e241-dde4-4da0-ad53-ab1aa37eb17e\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082600826_c.pdf\">2026082600826_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082600826_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-8767e241-dde4-4da0-ad53-ab1aa37eb17e\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CSPC Pharmaceutical Group (HKG: 1093) announced that SYS6090 (JMT108), a PD\u20111\/IL\u201115 bispecific fusion protein, has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[171,855,18,80],"class_list":["post-76799","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cspc-pharmaceutical","tag-hkg-1093","tag-pd-1-l1","tag-priority-reviews"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CSPC&#039;s PD-1\/IL-15 Bispecific SYS6090 (JMT108) Granted FDA Fast Track for MSS\/pMMR Metastatic Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CSPC Pharmaceutical Group (HKG: 1093) announced that SYS6090 (JMT108), a PD\u20111\/IL\u201115 bispecific fusion protein, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with microsatellite\u2011stable (MSS) or proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC) who have progressed on standard systemic therapies. The designation recognizes a differentiated immunotherapy approach aimed at one of oncology&#039;s most resistant tumor types \u2014 the immunologically &quot;cold&quot; MSS\/pMMR mCRC population with profound unmet need.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=76799\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CSPC&#039;s PD-1\/IL-15 Bispecific SYS6090 (JMT108) Granted FDA Fast Track for MSS\/pMMR Metastatic Colorectal Cancer\" \/>\n<meta property=\"og:description\" content=\"CSPC Pharmaceutical Group (HKG: 1093) announced that SYS6090 (JMT108), a PD\u20111\/IL\u201115 bispecific fusion protein, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with microsatellite\u2011stable (MSS) or proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC) who have progressed on standard systemic therapies. The designation recognizes a differentiated immunotherapy approach aimed at one of oncology&#039;s most resistant tumor types \u2014 the immunologically &quot;cold&quot; MSS\/pMMR mCRC population with profound unmet need.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=76799\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T06:39:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76799#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76799\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CSPC&#8217;s PD-1\\\/IL-15 Bispecific SYS6090 (JMT108) Granted FDA Fast Track for MSS\\\/pMMR Metastatic Colorectal Cancer\",\"datePublished\":\"2026-08-27T06:39:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76799\"},\"wordCount\":489,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CSPC Pharmaceutical\",\"HKG: 1093\",\"PD-1\\\/L1\",\"Priority reviews\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76799#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76799\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=76799\",\"name\":\"CSPC's PD-1\\\/IL-15 Bispecific SYS6090 (JMT108) Granted FDA Fast Track for MSS\\\/pMMR Metastatic Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-27T06:39:41+00:00\",\"description\":\"CSPC Pharmaceutical Group (HKG: 1093) announced that SYS6090 (JMT108), a PD\u20111\\\/IL\u201115 bispecific fusion protein, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with microsatellite\u2011stable (MSS) or proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC) who have progressed on standard systemic therapies. The designation recognizes a differentiated immunotherapy approach aimed at one of oncology's most resistant tumor types \u2014 the immunologically \\\"cold\\\" MSS\\\/pMMR mCRC population with profound unmet need.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76799#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76799\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76799#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CSPC&#8217;s PD-1\\\/IL-15 Bispecific SYS6090 (JMT108) Granted FDA Fast Track for MSS\\\/pMMR Metastatic Colorectal Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CSPC's PD-1\/IL-15 Bispecific SYS6090 (JMT108) Granted FDA Fast Track for MSS\/pMMR Metastatic Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"CSPC Pharmaceutical Group (HKG: 1093) announced that SYS6090 (JMT108), a PD\u20111\/IL\u201115 bispecific fusion protein, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with microsatellite\u2011stable (MSS) or proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC) who have progressed on standard systemic therapies. The designation recognizes a differentiated immunotherapy approach aimed at one of oncology's most resistant tumor types \u2014 the immunologically \"cold\" MSS\/pMMR mCRC population with profound unmet need.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=76799","og_locale":"en_US","og_type":"article","og_title":"CSPC's PD-1\/IL-15 Bispecific SYS6090 (JMT108) Granted FDA Fast Track for MSS\/pMMR Metastatic Colorectal Cancer","og_description":"CSPC Pharmaceutical Group (HKG: 1093) announced that SYS6090 (JMT108), a PD\u20111\/IL\u201115 bispecific fusion protein, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with microsatellite\u2011stable (MSS) or proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC) who have progressed on standard systemic therapies. The designation recognizes a differentiated immunotherapy approach aimed at one of oncology's most resistant tumor types \u2014 the immunologically \"cold\" MSS\/pMMR mCRC population with profound unmet need.","og_url":"https:\/\/flcube.com\/?p=76799","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-27T06:39:41+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=76799#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=76799"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CSPC&#8217;s PD-1\/IL-15 Bispecific SYS6090 (JMT108) Granted FDA Fast Track for MSS\/pMMR Metastatic Colorectal Cancer","datePublished":"2026-08-27T06:39:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=76799"},"wordCount":489,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CSPC Pharmaceutical","HKG: 1093","PD-1\/L1","Priority reviews"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=76799#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=76799","url":"https:\/\/flcube.com\/?p=76799","name":"CSPC's PD-1\/IL-15 Bispecific SYS6090 (JMT108) Granted FDA Fast Track for MSS\/pMMR Metastatic Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-27T06:39:41+00:00","description":"CSPC Pharmaceutical Group (HKG: 1093) announced that SYS6090 (JMT108), a PD\u20111\/IL\u201115 bispecific fusion protein, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with microsatellite\u2011stable (MSS) or proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC) who have progressed on standard systemic therapies. The designation recognizes a differentiated immunotherapy approach aimed at one of oncology's most resistant tumor types \u2014 the immunologically \"cold\" MSS\/pMMR mCRC population with profound unmet need.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=76799#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=76799"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=76799#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CSPC&#8217;s PD-1\/IL-15 Bispecific SYS6090 (JMT108) Granted FDA Fast Track for MSS\/pMMR Metastatic Colorectal Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76799","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=76799"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76799\/revisions"}],"predecessor-version":[{"id":76801,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76799\/revisions\/76801"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=76799"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=76799"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=76799"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}